- Home
- LSPD vs NVCR Comparison
LSPD vs NVCR Comparison
Compare LSPD & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LSPD | NVCR |
|---|---|---|
| Founded | 2005 | 2000 |
| Country | Canada | Switzerland |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | LSPD | NVCR |
|---|---|---|
| Price | $9.42 | $13.59 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 6 |
| Target Price | $13.40 | ★ $27.75 |
| AVG Volume (30 Days) | 1.2M | ★ 2.6M |
| Earning Date | 01-01-0001 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $655,353,000.00 |
| Revenue This Year | $15.43 | $10.50 |
| Revenue Next Year | $11.26 | $4.02 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.28 |
| 52 Week Low | $7.34 | $9.82 |
| 52 Week High | $14.34 | $21.55 |
Technical Indicators
Market Signals| Indicator | LSPD | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 42.04 | 58.94 |
| Support Level | $8.41 | $12.66 |
| Resistance Level | $12.55 | $14.13 |
| Average True Range (ATR) | 0.38 | 1.06 |
| MACD | 0.08 | 0.39 |
| Stochastic Oscillator | 82.73 | 70.04 |
Price Performance
Historical ComparisonAbout LSPD Lightspeed Commerce Inc. Subordinate Voting Shares
Lightspeed Commerce Inc provides an omni-channel commerce-enabling SaaS platform. Its software platform provides customers with the functionality it needs to engage with consumers, manage their operations, accept payments, and grow their businesses. The company sells its platform through a direct sales force in the United States, Canada, United Kingdom, Australia, and other countries. It derives a majority of its revenue from the United States.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.